Bashir, Q., Thall, P. F., Milton, D. R., Fox, P. S., Kawedia, J. D., Kebriaei, P., Shah, N., Patel, K., Andersson, B. S., Nieto, Y. L., Valdez, B. C., Parmar, S., Rondon, G., Delgado, R., Hosing, C., Popat, U. R., Oran, B., Ciurea, S. O., Lin, P., Weber, D. M., Thomas, S. K., Lee, H. C., Manasanch, E. E., Orlowski, R. Z., Williams, L. A., Champlin, R. E., & Qazilbash, M. H. (2019). conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet, 6(5), e266–e275. http://access.bl.uk/ark:/81055/vdc_100081424811.0x000001